Evidence map›Paper›PMID 41322193›Full record

ArticleMolecular therapy. Oncology2025

Clinical translation of TLR agonist-modified silicified cancer cell therapy supported by humanized mouse models.

Mara P Steinkamp, Danielle Burke, Madigan Morrison, Irina Lagutina, Lillian Fitzpatrick, Rita E Serda

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mara P SteinkampDepartment of Pathology, University of New Mexico Health Science Center, Albuquerque, NM 87131, USA.
Danielle BurkeDepartment of Pathology, University of New Mexico Health Science Center, Albuquerque, NM 87131, USA.
Madigan MorrisonInternal Medicine, University of New Mexico Health Science Center, Albuquerque, NM 87131, USA.
Irina LagutinaUniversity of New Mexico Comprehensive Cancer Center Animal Models Shared Resource, Albuquerque, NM 87131, USA.
Lillian FitzpatrickUniversity of New Mexico Comprehensive Cancer Center Animal Models Shared Resource, Albuquerque, NM 87131, USA.
Rita E SerdaInternal Medicine, University of New Mexico Health Science Center, Albuquerque, NM 87131, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Humanized patient-derived xenograft (huPDX) mouse models are crucial for evaluating the clinical translation of new immune therapeutics. Silicification of cancer cells renders the cells non-viable with enhanced stability and silica surface functionalization, enabling adsorption of pathogen-associated molecular patterns to attract and activate myeloid cells. While strong therapeutic efficacy has been demonstrated in syngeneic mouse models of ovarian cancer, promising results do not always translate to effective treatments for patients. To support clinical translation, therapeutic responses to silicified ovarian cancer cells were studied in huPDXs. Three humanized mouse models using different immunocompromised strains were used to evaluate recent advances in the field, including the addition of the

Indexed as

cell-based therapyhumanized micemilky spotsNBSGWomentumovarian cancerpatient-derived xenograftsilicified cancer cellsToll-like receptor agonist

Identifiers

PMID41322193
PMCPMC12657293

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.